Skip to Content

Venclexta (venetoclax) Disease Interactions

There are 4 disease interactions with Venclexta (venetoclax):

Moderate

Venetoclax (Includes Venclexta) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

In vitro studies demonstrated that venetoclax is predominantly metabolized in the liver by CYP450 3A4/5. Based on pharmacokinetic analysis with subjects with mild and moderate hepatic impairment, the venetoclax exposures were similar to those with normal hepatic function; therefore, no dose adjustment is recommended in patients with mild or moderate hepatic impairment. Based on the drug metabolism, an increase in adverse events might result in patients with moderate to severe hepatic impairment. It is recommended to monitor patients with moderate to severe hepatic impairment carefully for signs of toxicity during the initiation and the weekly dose ramp-up phase. Caution is advised when using this agent in patients with severe hepatic impairment as it pharmacokinetics has not been studied.

Moderate

Venetoclax (Includes Venclexta) ↔ Neutropenia

Moderate Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral, Fever, Neutropenia

Venetoclax can cause neutropenia. It is recommended to monitor for fever and signs suggestive of an infection. Monitor complete blood count during the course of therapy and reduce dose or interrupt treatment for severe neutropenia. Therapy with this agent should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.

Moderate

Venetoclax (Includes Venclexta) ↔ Tls/Renal

Moderate Potential Hazard, Moderate plausibility

Applies to: Tumor Lysis Syndrome, Renal Dysfunction

Based on pharmacokinetic analysis with subjects with mild and moderate renal impairment, the venetoclax exposures were similar to those with normal renal function; therefore, no dose adjustment is recommended in these patients. The pharmacokinetics of venetoclax has not been studied in subjects with severe renal impairment. Patients with reduced renal function are at increased risk of tumor lysis syndrome (TLS) and these patients may require more intensive monitoring and care to reduce the risk of TLS at the start of treatment. Patients should be assessed for risk factor that may contribute to an increase risk for TLS and complete blood chemistries should be monitored regularly. Dose interruption is recommended if needed based on clinical findings.

Moderate

Venetoclax (Includes Venclexta) ↔ Vaccination

Moderate Potential Hazard, Moderate plausibility

Applies to: Vaccination

The administration of live attenuated vaccines should be avoided prior to, during, or after during therapy with venetoclax until B-cell recovery occurs. It is recommended to be up-to-date with all required immunizations, as recommended by current immunization guidelines, before initiating therapy. The safety and efficacy of immunization with live attenuated vaccines during or following venetoclax therapy have not been studied. Venetoclax may interfere with the response to immunization and the vaccinations may be less effective.

Venclexta (venetoclax) drug Interactions

There are 335 drug interactions with Venclexta (venetoclax)

Venclexta (venetoclax) alcohol/food Interactions

There is 1 alcohol/food interaction with Venclexta (venetoclax)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide